New drug promises to save hundreds of thousands of victims of Alzheimer’s disease from the terrible hallucinations and paranoia. This tool is intended to combat psychosis, often observed in patients with senile dementia.
Scientists are developing new drug product intended for the treatment of psychosis in patients with senile dementia. Statistics show that severe hallucinations, paranoia and other symptoms of psychosis are observed in approximately half of the victims of dementia. While psychosis is not a side effects caused by any medication Alzheimer. However, the study of the action drug drug called pimavanserin gives some hope to people with already developed psychosis.
Currently, victims of senile dementia mainly rely when dealing with similar symptoms on the medication category of antipsychotics, however, they have a very negative impact on the course of Alzheimer sometimes speeding it up twice, and also increasing the risk of falls and resulting lethargy. Only in the UK antipsychotics cause 1 660 strokes and 1,800 preventable deaths. In contrast, pimavanserin which affects specific nerve receptors in the brain significantly improves the condition of the victims of psychosis without significant side effects. Scientists from the University of Exeter has already tested the effectiveness of this drug on 90 patients with Alzheimer’s, giving the same number of patients a placebo.
Currently, the broader the third part of a clinical trial pimavanserin held in the US, the results will be examined in detail by the regulatory health agencies in Europe. Informed community to help victims of Alzheimer’s disease called on the governments of various countries to approve pimavanserin for use among patients with senile dementia who also have Parkinson’s disease.